Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action.
Studies were designed to investigate differences in pharmacokinetics and pharmacodynamics of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine (SPA) between lean and obese Zucker rats. In conscious rats, time courses of the effect on heart rate and parameters of lipid metabolism (fatty acids, glycerol) were monitored in combination with the decline of drug concentrations after i.v. administration of 100 microgram SPA in 15 min. Small differences in pharmacokinetics of SPA were observed between lean and obese rats. Values for clearance and volume of distribution were 1.2 +/- 0.2 ml/min and 88 +/- 10 ml in lean, and 1.6 +/- 0.1 ml/min and 110 +/- 7 ml in obese animals, respectively. Modelling of the concentration-heart rate relationship on the basis of the sigmoidal Emax model revealed no difference in EC50 (99 +/- 12 and 118 +/- 17 ng/ml) or Emax (-191 +/- 16 and -185 +/- 22 bpm) between the lean and obese rats. The metabolic effects of SPA were totally different between lean and obese rats. Potent (EC50 = 18 +/- 3 ng/ml) inhibition of lipolysis was observed in the lean rats. In obese rats, SPA was less potent (EC50 = 109 +/- 36 ng/ml) resulting in short lasting antilipolytic effect. Furthermore, administration of SPA resulted in a significant decrease in insulin concentrations. These findings show that changes in glucose and lipid metabolism may be associated with an altered sensitivity to the antilipolytic actions of adenosine A1 receptor agonists.
Leiden/Amsterdam Center for Drug Research, Divisions of Pharmacology, 2300 RA Leiden, The Netherlands.
E A
EA
van Schaick
K P
KP
Zuideveld
H E
HE
Tukker
M W
MW
Langemeijer
A P
AP
Ijzerman
M
M
Danhof
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects*; D007328:Insulin / Q000097:blood; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D009765:Obesity / Q000378:metabolism*; D058906:Purinergic P1 Receptor Agonists; D051381:Rats; D011924:Rats, Zucker
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; C109113:N(6)-(4-sulfophenyl)adenosine; D058906:Purinergic P1 Receptor Agonists; D000241:Adenosine